KRAS and non-small cell lung carcinoma: Current testing options for actionable mutations in NSCLC using cfDNA and a similar ddPCR-based (droplet digital) workflow for rapid result generation include the epidermal growth factor receptor (EGFR) sensitizing mutations, including ΔE746-A750, L858R, T790M, the KRAS proto-oncogene variants KRAS G12C/D/V, and B-Raf proto-oncogene variant BRAF V600E [4].